Covid19, Vaccine Hesitancy, Vaccine Refusal
Conditions
Keywords
Vaccine Completion, COVID19 Testing, COVID19 Education, Point of Care Testing, Healthcare Personnel Education, Healthcare Disparities
Brief summary
This project is a 2-year study to investigate vaccine hesitancy and vaccine completion among vulnerable communities in the Southeastern Louisiana region. This study will be used to track COVID-19 vaccine completion among patients who seek testing, either as in-person or purchasing at home COVID testing, from pharmacies, urgent cares and clinics using a rapid vaccine education model delivered at the point of care.
Detailed description
This project is a 2-year study to investigate vaccine hesitancy and vaccine completion among vulnerable communities in the Southeastern Louisiana region. This study will be used to track COVID-19 vaccine completion among patients who seek testing, either as in-person or purchasing at home COVID testing, from pharmacies, urgent cares and clinics. The proposal will introduce a rapid vaccination education model to be delivered at the point of COVID-19 testing by pharmacy students, pharmacy technicians, nurse's aides and other health care personnel and includes monitoring for COVID-19 vaccine completion among enrolled patients. Investigators anticipate an increase in COVID-19 vaccine completion rates for those who participate in the rapid vaccination education model.
Interventions
BEHAVIORALCOVID-19 Vaccine Education at the Point of COVID-19 Testing
A rapid vaccination education model to be delivered at the point of COVID-19 testing by pharmacy students, pharmacy technicians, nurse's aides and other health care personnel. The intervention will include: 1) 15 minute vaccine counseling, 2) print material 3) referral to a dedicated vaccine website with feedback forums and 4) opportunity to sign-up for one-on-one vaccine counseling with a clinical pharmacist
Sponsors
Xavier University of Louisiana.
National Institute on Minority Health and Health Disparities (NIMHD)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
Yes
Inclusion criteria
* Unvaccinated adult participants, 18-99 years of age, able to provide informed consent, and to communicate in English, Spanish or Arabic. Also, individuals with incomplete vaccination (primary series or COVID-19 booster).
Exclusion criteria
* Persons fully vaccinated for COVID-19 (including primary series and boosters), persons with any documented allergies to components of the COVID-19 vaccines, or contraindications to receiving a COVID-19 vaccine.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| COVID-19 Vaccine Completion Upon Education | 9 months intervention | COVID-19 vaccination completion verified by the Louisiana LINKS© system, defined as receipt of all recommended doses of a COVID-19 vaccine during the 9-month intervention period following education at the point of COVID-19 testing. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Vaccine Hesitancy Likelihood Scale | 9 months post intervention | Measured on a 5-point scale indicating likelihood to be vaccinated. The scale ranges from 1 (Not at all likely to be vaccinated), 2 (Not likely to be vaccinated), 3 (No opinion/Undecided about vaccination), 4 (Likely to be vaccinated) to 5 (Very likely to be vaccinated) |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORSara Al-Dahir, PharmD
Xavier University of Louisiana.
PRINCIPAL_INVESTIGATORKlaus Heyer, PhD
Nunez Community College
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Categorical <=18 years | 14 Participants |
| Age, Categorical >=65 years | 20 Participants |
| Age, Categorical Between 18 and 65 years | 343 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 47 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 330 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| participants received covid-19 test or not did not receive COVID-19 test | 69 Participants |
| participants received covid-19 test or not Received COVID-19 test | 308 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 150 Participants |
| Race (NIH/OMB) More than one race | 57 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 170 Participants |
| Received COVID-19 Vaccine Before Study Started Between 2020-2022 Did not receive Covid-19 Vaccine Prior to Study 2020-2022 | 207 Participants |
| Received COVID-19 Vaccine Before Study Started Between 2020-2022 Received Covid-19 Vaccine Prior to Study 2020-2022 | 170 Participants |
| Region of Enrollment United States | 377 Participants |
| Sex: Female, Male Female | 143 Participants |
| Sex: Female, Male Male | 234 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 0 |
| other Total, other adverse events | 0 / 0 |
| serious Total, serious adverse events | 0 / 0 |
Outcome results
None listed